Moxalactam--absorption, excretion, distribution, and metabolism. 1982

J Shimada, and Y Ueda

Levels of moxalactam in serum of healthy volunteers after single intramuscular injection, slow bolus intravenous injection, or intravenous infusion were proportional to the dose given. After intravenous bolus injection of 1 g of moxalactam, the peak serum level was 201.0 micrograms/ml, the half-life (beta-phase) was 126 min, and the cumulative urinary excretion during a 10-hr period was 90.5% of the dose. The values for cefazolin in the same volunteers were similar to those for moxalactam. No accumulation of the drug in serum was found even after multiple intravenous injections of 1 g every 12 hr for five days. Probenecid administered orally did not significantly affect levels of moxalactam in serum or urinary recovery, an observation which suggests that renal excretion of moxalactam takes place mainly through glomerular filtration. The serum half-life (beta-phase) of moxalactam in subjects with a creatinine clearance rate of less than or equal to 10 ml/min was markedly prolonged. Concentrations of moxalactam in bile were higher than those of cefazolin in a crossover study. Concentrations in sputum were 1.84-2.11 micrograms/ml in individuals given 1 g by intravenous slow bolus injection. No active metabolite of moxalactam was detected in plasma or urine.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009070 Moxalactam Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. 1-Oxacephalosporin,6059-S,Disodium Latamoxef,Disodium Moxalactam,Festamoxin,Lamoxactam,Latamoxef,Lilly 127935,Ly-127935,Ly127935,Moxalactam Disodium,S-6059,Shiomarin,1 Oxacephalosporin,6059 S,6059S,Disodium, Moxalactam,Latamoxef, Disodium,Ly 127935,Moxalactam, Disodium,S 6059,S6059
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D002437 Cefazolin A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Cephazolin,Ancef,Cefamedin,Cefamezine,Cefazolin Sodium,Cephamezine,Cephazolin Sodium,Gramaxin,Kefzol,Sodium Cephazolin,Totacef,Cephazolin, Sodium,Sodium, Cefazolin,Sodium, Cephazolin
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics

Related Publications

J Shimada, and Y Ueda
January 1980, Clinical therapeutics,
J Shimada, and Y Ueda
February 1983, Yao xue xue bao = Acta pharmaceutica Sinica,
J Shimada, and Y Ueda
January 2021, Current drug metabolism,
J Shimada, and Y Ueda
November 2021, Expert opinion on drug metabolism & toxicology,
J Shimada, and Y Ueda
September 1984, Il Farmaco; edizione pratica,
J Shimada, and Y Ueda
March 1961, Journal of pharmaceutical sciences,
J Shimada, and Y Ueda
January 2006, Xenobiotica; the fate of foreign compounds in biological systems,
J Shimada, and Y Ueda
May 2002, Clinical pharmacology and therapeutics,
J Shimada, and Y Ueda
March 2016, Food & function,
Copied contents to your clipboard!